Amgen has reported that dazodalibep, a potential first-in-class CD40L antagonist designed to disrupt T-cell, B-cell and antigen-presenting-cell interaction, met the primary endpoint in the Phase III OASIZ 301 study in Sjögren's disease, with a clinically and statistically meaningful improvement in ESSDAI score at week 48 and early effect seen by week 4 in 621 randomised, double-blind, placebo-controlled patients. Amgen's candidate displayed a favourable safety profile: nasopharyngitis, urinary tract infection, hypertension and infusion reactions were mostly mild to moderate, discontinuations were low and thromboembolic and opportunistic infection rates looked similar across arms.

The programme sits in a thin advanced cohort: among roughly 40 CD40L-targeting assets in development globally, only dapirolizumab pegol, frexalimab and dazodalibep have reached Phase III, giving Amgen a credible lead in a systemic autoimmune setting that has no approved therapy in its US homeland and, in China, only telitacicept from RemeGen approved.

Commercially, Sjögren's is the second most common rheumatic disease and carries substantial unmet need through fatigue, chronic pain, organ involvement, neuropathy and raised lymphoma risk.